Shortage of injectable orphenadrine citrate

The American Society of Health-System Pharmacists reports a shortage of injectable orphenadrine citrate. This drug relaxes muscles and alleviates acute muscular-skeletal pain. It is in short supply because it is yet another drug whose production Bedford Laboratories contracted out to Ben Venue Labs. The latter voluntarily closed their facility. This drug actually has four US-approved manufacturers, but Akorn and Sagent did not provide a reason why their product is in short supply. Watson states that their product is back ordered because of production delays, with no further information as to the many possible reasons that delays occur.